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Abstract
Aim: Several studies reported the accompaniment of severe 
COVID-19 with comorbidities. However, there is not a sys-
tematic evaluation of all aspects of this association. There-
fore, this meta-analysis aimed to assess the association be-
tween all underlying comorbidities in COVID-19 infection 
severity. Methods: Electronic literature search was per-
formed via scientific search engines. After the removal of du-
plicates and selection of articles of interest, 28 studies were 
included. A fixed-effects model was used; however, if hetero-
geneity was high (I2 > 50%) a random-effects model was ap-
plied to combine the data. Results: A total of 6,270 individu-
als were assessed (1,615 severe and 4,655 non-severe pa-
tients). The median age was 63 (95% confidence interval [CI]: 
49–74) and 47 (95% CI: 19–63) years in the severe and non-
severe groups, respectively. Moreover, about 41% of pa-
tients had comorbidities. Severity was higher in patients 
with a history of cerebrovascular disease: OR 4.85 (95% CI: 
3.11–7.57). The odds of being in a severe group increase by 
4.81 (95% CI: 3.43–6.74) for a history of cardiovascular dis-
ease (CVD). This was 4.19 (95% CI: 2.84–6.19) for chronic lung 
disease and 3.18, 95% CI: 2.09–4.82 for cancer. The odds ra-
tios of diabetes and hypertension were 2.61 (95% CI: 2.02–
3.3) and 2.37 (95% CI: 1.80–3.13), respectively. Conclusions: 
The presence of comorbidities is associated with severity of 
COVID-19 infection. The strongest association was observed 
for cerebrovascular disease, followed by CVD, chronic lung 
disease, cancer, diabetes, and hypertension.
© 2021 S. Karger AG, Basel
Introduction
On December 31, 2019, several cases with pneumonia 
of unknown etiology were detected in Wuhan City, Hubei 
Province of China. Different potential causes such as in-
fluenza, avian influenza, adenovirus, severe acute respira-
tory syndrome coronavirus (SARS-CoV), and Middle 
East respiratory syndrome coronavirus (MERS-CoV) 
were assessed; however, the pathogen was not identified 
[1, 2]. Consequently, the causative viral disease called 
COVID-19 by the World Health Organization [1].The re-
cent COVID-19 Situation Report of the World Health 
Organization reported nearly 32.7 million diagnosed cas-
es with 991,000 deaths around the world until September 
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27, 2020 [3]. Older men and those with comorbidities 
such as cardiovascular disease (CVD), diabetes, hyper-
tension, and chronic obstructive pulmonary disease 
(COPD) were at the highest risk for the disease [4, 5] and 
higher rates of intensive care unit (ICU) admission [6].
Several studies reported the prevalence of comorbidi-
ties in COVID-19 patients [4, 7, 8]; however, a system-
atic evaluation of comorbidities to compare the relation 
of underlying medical conditions between severe and 
non-severe patients is lacking. Previous systematic re-
views and meta-analyses explored some but not all as-
pects of this association. Therefore, this meta-analysis 
aims to assess the association between all underlying co-
morbidities in COVID-19 infection severity. The results 
could guide healthcare professionals to encounter prop-
erly with COVID-19. Besides, it will help policy-makers 
to design a prevention plan as well as respond to CO-
VID-19 and its critical outcomes more preparedly.
Study Selection and Data Extraction
Inclusion and Exclusion Criteria
We included all relevant articles reporting clinical 
characteristics and epidemiological information on 
COVID-19 patients separately in a severe and non-se-
vere group. The criteria for severe disease include ICU 
admission, acute respiratory distress syndrome, need 
for supplemental oxygen or O2 saturation <93%, criti-
cally ill cases, and severe outcome (e.g., cardiac injury 
or decompensation, organ failure, or death/not sur-
vived) [9–15]. Case series with incomplete information 
as well as review articles, opinion articles, and letters 
not presenting original data as well as any type of pub-
lished data that only presented total patients were also 
excluded. The search strategy has been provided as sup-
plementary file #1.
Data Extraction
Two authors (M.H. and R.A.) screened and evaluated 
the titles and abstracts of citations independently, and 
then a third author (M.E.Kh.) checked the screening re-
sults. Then, the full text of potentially eligible articles was 
obtained and reviewed for further assessment according 
to the inclusion and exclusion criteria. Data extraction 
forms including the following items were also filled out: 
name of the first authors, date of publication, DOI, the 
number of reported cases, age, sex, and coexisting under-
lying diseases such as diabetes/type 2 diabetes as well as 
the number of patients in severe and non-severe groups. 
Wherever there was the word “hypertension” and “high 
blood pressure,” we considered them under the title of 
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“hypertension.” “Chronic obstructive pulmonary disease, 
COPD, Chronic lung diseases” were known as “chronic 
lung disease” in our study. “Cardiovascular disease, Cor-
onary heart disease, heart disease” were defined as “Car-
diovascular disease.” The medical term “Cancer” includ-
ed “Malignant tumor, Malignancy, Cancer, Carcinoma.” 
Besides, “Cerebrovascular diseases, Cerebral infraction” 
were considered under the title of “Cerebrovascular dis-
eases.”
Risk of Bias Assessment
Newcastle-Ottawa Scale was used to evaluate quality of 
the included studies. The Funnel plots were used to inves-
tigate possible publication bias.
Statistical Analysis
All Statistical analyses were performed using Stata ver-
sion 14 (StataCorp. 2015. Stata Statistical Software: Re-
lease 14, StataCorp LP, College Station, TX, USA). We 
employed “metaprop” command to calculate the pooled 
prevalence estimates of comorbidities with 95% confi-
dence. The associations between comorbidities and sever-
ity of disease, were expressed as odds ratios (ORs) and 
95% confidence intervals (CIs). Heterogeneity among the 
primary studies was evaluated by the forest plots, Co-
chran’s Q statistic, and I2 statistic. A random-effects mod-
el was used if heterogeneity was high (I2 > 50%); otherwise, 
a fixed-effects model was applied. Also, the publication 
bias was formally tested with Egger’s regression asymme-
try tests to determine the asymmetry of the funnel plots, 
where p < 0.10 was considered as evidence of bias.












Zang (19 Feb 2020) 140 57 58 82 33 38 25 44
Guan (28 Feb 2020) 1,099 47 173 926 540 100 73 386
Wang (7 Feb 2020) 138 56 36 102 22 73 14 49
Huang (24 Jan 2020) 41 49 13 28 11 19 2 9
Liu (9 Feb 2020) 12 62.5 2 10 2 6 0 4
Yang (24 Feb 2020) 52 59.5 32 20 21 14 11 6
JieLi (12 Feb 2020) 17 45.1 12 5 5 4 7 1
Zhou (28 Mar 2020) 191 56 54 131 38 81 16 56
Wang (16 Mar 2020) 69 42 14 55 7 25 7 30
Yuan (19 Mar 2020) 27 60 17 10 4 8 3 12
Yuan (29 Mar 2020) 19 40 11 8 5 3 6 5
Chen (17 Mar 2020) 274 62 113 161 83 88 30 73
Young (3 Mar 2020) 18 47 6 12 2 7 4 5
Wu (27 Mar 2020) 280 43.12 83 197 45 106 34 91
Li, KunhuaMS (29 Feb 2020) 83 45.5 25 58 15 29 10 29
Wei-jie Guan (26 Mar 2020) 1,590 – 254 1,336 – – – –
Gao (17 Mar 2020) 43 – 15 28 9 17 6 11
Chen (19 Feb 2020) 21 56.3 11 10 10 7 1 3
Chen (10 Mar 2020) 150 – 24 126 – – – –
Yang-kai Li (30 Mar 2020) 61 51 36 25 10 14 4 22
Qin (12 Mar 2020) 452 58 286 166 155 80 131 86
Wang (31 Mar 2020) 116 54 57 59 33 34 24 25
Wan (21 Mar 2020) 135 47 40 95 21 51 19 44
Shi (18 Mar 2020) 487 49 438 46 36 223 13 215
Mo (16 Mar 2020) 155 85 70 54 55 31 30 39
Liu (28 Feb 2020) 78 11 67 38 7 32 5 35
Shi (25 Mar 2020) 416 82 334 64 44 63 38 173
Peng (1 Apr 2020) 112 16 96 62 7 52 9 44
* Age is reported as median for all studies. ** N is the absolute number in each column.
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Results
Characteristics of Included Studies
In the initial search, 1,043 articles were found in dif-
ferent databases. 486 papers were excluded due to being 
duplicates. All papers were screened by reading their title 
and abstract, and 489 studies were excluded because of 
irrelevant data. Figure 1 shows the search details, and Ta-
ble 1 shows the details of the included studies. In total, 28 
studies (27 retrospective cross-sectional and 1 case series 
article) on 6,276 patients (32.2% female) were included 
(Fig. 1). All studies were conducted between January and 
April 2020 during the novel coronavirus (SARS-2-CoV) 
outbreak. The heterogeneity of all selected studies was 
low (I2 between 0.0–30) except for hypertension (I2 = 
58.6). A total of 1,615 individuals were identified as severe 
disease whereas 4,655 individuals had the non-severe dis-
ease. The median age was 63 (95% CI: 49–74) years in the 
severe group compared to 47 (95% CI: 19–63) years in the 
non-severe group. The proportions of males/females, 
overall and by COVID-19 severity, were 1.18 and 1.35, 
respectively. The disease was more common in men over-
all (54.2%) and by COVID-19 severity (68%).
Prevalence of Underlying Diseases in COVID-19
We found that 41.1% of patients had associated co-
morbidities such as hypertension (20.9%), diabetes 
(9.96%), and CVD (4.8%) (Fig. 2; Table 2).
Figure 3 illustrates the relationship between associated 
comorbidities and disease severity. The most strongly as-
sociated comorbidities with severity of COVID-19 were 
cerebrovascular disease (OR 4.85, 95% CI: 3.11–7.57), 
CVD (OR 4.81, 95% CI: 3.43–6.74), and chronic lung dis-
ease (OR 4.19, 95% CI: 2.84–6.19) followed by cancer (OR 
3.18, 95% CI: 2.09–4.82), diabetes (OR 2.61, 95% CI: 
2.02–3.39), and hypertension (OR 2.37, 95% CI: 1.80–
3.13), respectively (Fig. 3).
Discussion
Care of COVID-19 patients is presenting a major chal-
lenge for health care systems. This includes dealing with 
rapidly growing numbers of patients, inadequate re-
sponse to current treatments, limited care staffing, and 
inadequate medical supplies [16]. Moreover, many fac-
tors can lead to severe COVID-19, especially in older 
adults. Disease severity was defined as the need for hos-
pitalization, admission to an ICU, and death [17]. Clas-
sification of COVID-19 patients into severe and non-se-
vere cases improves patient outcomes by providing the 
chance of effective individual assessment of patients [18]. 
Previous studies demonstrated that comorbidities such as 
diabetes, COPD, hypertension, and malignancy may lead 
to poorer prognosis [16, 19–22]. Therefore, in this study, 
we tried to explore the impact of comorbidities on the 
prognosis of the COVID-19 infection (Fig. 3).
We found disease severity was highly associated with 
the presence of cerebrovascular disease (OR 4.85, p < 0.01, 
I2: 2.2%). It seems that the nervous system disease may be 
linked to the pathogenesis of COVID-19. In addition to 
the respiratory tract system, the nervous system may be 
invaded by SARS-CoV-2 via a hematogenous system or 
retrograde neuronal route, the same as SARS and MERS 
viruses leading to a wide spectrum of neurological mani-
festations from taste and smell impairment to acute cere-
brovascular diseases and impaired consciousness [23]. 
Furthermore, lymphocyte counts are lower for patients 
with CNS involvement. This might be explained by im-
mune suppression in patients with COVID-19 with CNS 
involvement, especially in severe cases. Moreover, an 
acute cerebrovascular disease with severe infection leads 
to rapid clinical deterioration contributing to a high mor-
tality rate [23].
Preexisting CVD is also an important underlying dis-
ease for more severe COVID-19 accompanied by worse 
clinical outcomes [24]. Our meta-analysis revealed that 

























































nificantly increased risk of severe COVID-19 disease 
(Fig.  3). In a meta-analysis on 6 published studies on 
1,527 patients with COVID-19 from China, the preva-
lence of diabetes, cardio-cerebrovascular disease and hy-
pertension was reported to be 9.7, 16.4 and 17.1%, respec-
tively [24]. Besides, diabetes and hypertension were 
shown to increase the risk of severity or requiring ICU 
admission by 2-fold while this figure was reported to be 
3-fold for cardio-cerebrovascular disease [24]. Also, in a 
study by Clerkin et al. [24], CVD was associated with dis-
ease severity and ICU admission by 4.4 times (95% CI 
2.64–7.47). Furthermore, disease severity is associated 
with higher case fatality rate. In addition, in a study by Shi 
et al. [25], it was shown that preexisting CVDs may pre-
dispose COVID-19 patients to COVID-19-induced heart 
injury.
Our study also showed that chronic lung disease was sig-
nificantly related to the development of severe COVID-19 
infection (OR 4.19 p < 0.01) (Fig. 3). Severe COPD is also a 
risk factor for severe COVID-19. In a meta-analysis con-
ducted on 7 studies, COPD was shown to increase the risk 
of developing severe COVID-19 infections [21]. In a case 
series report from the Chinese Center for Disease Control 
and Prevention, the overall case fatality rate was 2.3%, while 
this figure was 6.3% for people with COPD [26]. In a study 
by Jain and Yuan [27], COPD was shown as the strongest 
predictive factor for disease severity (OR 6.42, 95% CI 2.44–
16.9) as well as ICU admission (OR 17.8, 95% CI 6.56–48.2).
Malignancy was also a risk factor for COVID-19 sever-
ity. The results of our pooled analysis also show that pre-
existing cancer is associated with up to 3.18-fold higher 
risk of severe COVID-19 (Fig. 3). Infections are the lead-
Table 2. Baseline underlying disease of patients with COVID-19

















Zang (19 Feb 2020) 8 9 4 3 22 20 – – 2 0 – –
Guan (28 Feb 2020) 28 53 10 17 40 123 4 11 4 6 3 7
Wang (7 Feb 2020) 8 6 6 1 21 22 6 1 3 1 4 6
Huang (24 Jan 2020) 1 7 3 3 2 4 – – 1 0 0 1
Liu (9 Feb 2020) 0 1 1 3 1 2 – – 1 0 0 0
Yang (24 Feb 2020) 7 2 3 2 – – 7 0 2 2 1 1
JieLi (12 Feb 2020) – – – – 1 0 – – – – – –
Zhou (28 Mar 2020) 17 19 13 2 26 32 – – 4 2 0 2
Wang (16 Mar 2020) 6 1 5 3 – – – – 2 2 1 3
Yuan (19 Mar 2020) 6 0 3 0 – – 1 0 – – 1 0
Yuan (29 Mar 2020) 2 0 4 0 3 0 – – – – – –
Chen (17 Mar 2020) 24 23 17 7 54 39 4 0 11 7 5 2
Young (3 Mar 2020) 1 0 – – 4 0 – – – – – –
Wu (27 Mar 2020) – – – – – – – – 4 0 3 2
Li (29 Feb 2020) 7 0 1 0 2 3 – – 4 1
Guan (26 Mar 2020) 45 85 20 39 88 181 15 15 15 9 9 9
Gao (17 Mar 2020) 6 1 1 2 6 7 – – – – – –
Chen (19 Feb 2020) 2 1 – – 4 1 – – – – – –
Chen (10 Mar 2020) 5 15 6 3 14 35 – – – – – –
Yang (30 Mar 2020) 2 0 6 2 2 2 – – 7 3 – –
Qin (12 Mar 2020) 53 22 24 3 105 30 8 3 9 3 10 4
Wang (31 Mar 2020) 10 8 – – 20 23 6 1 – – – –
Wan (21 Mar 2020) 9 3 6 1 4 9 – – – – 3 1
Shi (18 Mar 2020) 7 22 4 7 26 73 – – – – 2 3
Mo (16 Mar 2020) 12 3 7 0 22 15 7 0 – – 5 2
Liu (28 Feb 2020) 2 3 – – 2 6 1 1 2 2
Shi (25 Mar 2020) 20 40 36 29 49 78 13 9 6 6 7 2
Peng (1 Apr 2020) 4 19 – – 10 82 – – – – – –
CVD, cardiovascular disease.










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ing cause of mortality in malignancy [28]. The underlying 
disease, malignancy-related treatments as well as accom-
panied comorbidities are 3 main reasons for susceptibility 
to infections in this group of patients. Both malignancy 
and its related treatment result in compromised immune 
systems and a higher risk of infection [28]. Moreover, ac-
companied comorbidities were previously shown to in-
crease the risk of mortality in MERS-CoV infection [28]. 
Furthermore, Liang et al. [29] showed that among patients 
with malignancy, older age was the only risk factor for se-
vere events (OR 1.43, 95% CI 0.97–2.12; p = 0.072).
In this meta-analysis, we found that diabetes (OR 2.61, 
95% CI: 2.02–3.39) and hypertension (OR 2.37, 95% CI: 
1.80–3.13) also increase the risk of severity in COVID-19. 
Diabetes was an important risk factor for mortality in pa-
tients infected with pandemic influenza A (H1N1), SARS-
CoV as well as MERS-CoV [30]. In a study that was con-
ducted by Fadini et al. [31], the pooled rate ratio of dia-
betes among patients with severe disease compared to 
those with the non-severe disease was 2.26 (95% CI 1.47–
3.49). Moreover, diabetes-related complications as the in-
dicators of advanced diabetes may increase the risk of 
mortality in COVID-19 [19].
Globally, hypertension is a prevalent disease reported 
in 26% of the population worldwide [22]. However, pre-
vious studies showed controversial results regarding the 
association between hypertension and COVID-19 sever-
ity [22]. In a study by Lippi et al. [22], hypertension was 
shown to increase both the severity and mortality of CO-
VID-19 by ∼2.5-fold. This effect was mainly demonstrat-
ed in people older than the age of 60, in a meta-regression 
[22]. Besides, Jain and Yuan [27] showed that hyperten-
sion increased disease severity and ICU admission by 3.7 
times (95% CI 2.22–5.99). In a meta-analysis by Yang et 
al. [6] on 8 studies, comorbidities such as hypertension 
(OR 2.36, 95% CI: 1.46–3.83), respiratory system disease 
(OR 2.46, 95% CI: 1.76–3.44), and CVDs (OR 3.42, 95% 
CI: 1.88–6.22) were shown to impose a higher risk for dis-
ease severity. However, diabetes did not have a statisti-
cally significant effect (OR2.07, 95% CI: 0.89–4.82) [6].
In general, our findings indicate that individuals with 
associated comorbidities are more susceptible to severe 
COVID-19 infection. Those at the highest risk for severe 
disease include people with underlying conditions such 
as cerebro-cardiovascular disease, chronic respiratory 
disease, cancer, diabetes, and hypertension.
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The key strengths of this study are its quality assess-
ments of studies, large sample size, and desirable I2 of 
chosen studies. The funnel plot results indicated that our 
selected studies had high precision which mostly plotted 
near the average (Fig. 4).
One issue with the current study was that the generaliz-
ability of findings to other populations was unclear be-
cause of published reports being restricted to China and a 
few other countries. Moreover, we do not have detailed 
data on the number of comorbidities/vascular risk factors 
and the severity of COVID-19. The heterogeneity of dis-
ease severity definition across studies was the other limita-
tion of current study in which any of the following condi-
tions are included as a severe case: ICU admission, receipt 
of mechanical ventilation or SpO2 < 90%, development of 
cardiac injury or end organ failure, and mortality.
In addition, most selected studies did not specify the 
type of cerebrovascular disease except for 2 in which cere-
brovascular disease was defined as cerebral infarction. 
Furthermore, considering uncertainty about data collec-
tion methods and consistency, the results should be inter-
preted cautiously.
Conclusion
The findings indicate that the presence of associated 
comorbidities is associated with worse outcome in CO-
VID-19 infection. Cerebrovascular disease was the most 
strongly predictive comorbidity for severe disease, fol-
lowed by CVD, chronic lung disease, cancer, diabetes, 
and hypertension.
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